Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 2, 2002

View Archived Issues

Novel calcium receptor modulators and their use described in Aventis patent

Two Shionogi patents describe novel immunosuppressant agents

Merck reports development of inhibitors of p38 kinase

Novel cytokine and T-cell production inhibitors and their use in cancer, arthritis, etc.

KN-62 inhibits MAPK/c-Myc activation and proliferation in human keratinocytes

NO-1886 combined with exercise may prevent development of atherosclerosis in the elderly

The antifungal clotrimazole exhibits neuroprotective effects in vitro

PARP inhibitor GPI-6150 effective in rat model of colitis

Antiamnesic effects of DM-232 demonstrated in mice and rats

Efficacy of IS-741 on spontaneous colitis in transgenic rat model

New inhibitors of malonyl-CoA decarboxylase and their use in heart failure, diabetes, obesity, etc.

Vical updates progress of Leuvectin program

Enrollment completed in DIAMOND and SILVER ALT-711 trials

Extended-spectrum oxazolidinone selected for clinical development

INS-37217, a next-generation P2Y2 agonist with an enhanced duration of action

Phase III data in immunocompromised patient population presented for micafungin

Positive results emerge from pilot trial of SCV-07 in tuberculosis

Polyphenon enters pivotal phase III trial for genital warts

Idec gains license to develop HMN-214

IND cleared for Alzhemed phase II

Orphan drug grant for Endostatin trial

Clinical efficacy and safety of ACH-126443 in HBV demonstrated in phase I/II clinical trial

InterMune and Array BioPharma collaborate on hepatitis drug discovery

Twelve-month data show efficacy of anecortave acetate in wet AMD

Iseganan fails to meet primary endpoint in ulcerative oral mucositis phase III trial

deCODE and Merck & Co. form obesity alliance

Triangle's Coviracil outperforms Zerit in phase III trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 12, 2025.
Deep Apple signs big Novo deal for cardiometabolic small molecules
BioWorld
Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...
23andme genetic privacy concerns garner Congressional scrutiny
BioWorld MedTech
The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...
3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race
BioWorld
3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...